-
Letter to the Editor
Comment On: Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(11):580-581
11-01-2016
Summary
Letter to the EditorComment On: Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(11):580-581
11-01-2016Views63Medeiros e Melo et al report a case of a patient with pre-eclampsia and peripartum cardiomyopathy (PPCM) successfully treated with the dopamine receptor D2 agonist cabergoline. Treatment with the dopamine receptor agonist bromocriptine is currently being evaluated in a multicenter clinical trial (NCT00998556) that is based on the concept of dopamine agonists inhibiting the enzymatic […]See moreViews63
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Letter to the EditorComment On: Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(11):580-581
11-01-2016Views63Medeiros e Melo et al report a case of a patient with pre-eclampsia and peripartum cardiomyopathy (PPCM) successfully treated with the dopamine receptor D2 agonist cabergoline. Treatment with the dopamine receptor agonist bromocriptine is currently being evaluated in a multicenter clinical trial (NCT00998556) that is based on the concept of dopamine agonists inhibiting the enzymatic […]See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Letter to the Editor
Use of Prolactin Inhibition in the Treatment of Peripartum Cardiomyopathy
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(9):477-478
09-01-2016
Summary
Letter to the EditorUse of Prolactin Inhibition in the Treatment of Peripartum Cardiomyopathy
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(9):477-478
09-01-2016Views89I certainly agree with Dr. Melo and colleagues that newer treatments are necessary for the therapy of peripartum cardiomyopathy (PPCM); and particularly in those areas of the world with higher mortality and morbidity rates. My hope is to encourage Dr. Melo and colleagues, or others, to carry out a carefully controlled study of either cabergoline […]See moreViews89This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Letter to the EditorUse of Prolactin Inhibition in the Treatment of Peripartum Cardiomyopathy
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(9):477-478
09-01-2016Views89I certainly agree with Dr. Melo and colleagues that newer treatments are necessary for the therapy of peripartum cardiomyopathy (PPCM); and particularly in those areas of the world with higher mortality and morbidity rates. My hope is to encourage Dr. Melo and colleagues, or others, to carry out a carefully controlled study of either cabergoline […]See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Letter to the Editor
Cabergoline in the Treatment of Peripartum Cardiomyopathy
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
08-01-2016
Summary
Letter to the EditorCabergoline in the Treatment of Peripartum Cardiomyopathy
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
08-01-2016Views95It is premature to make a recommendation for treatment of peripartum cardiomyopathy (PPCM) with prolactin inhibition (bromocriptine or cabergoline) as in the one-case report of Melo et al. There are now multiple reports of trials for PPCM subjects in the use prolactin inhibition treatment compared with non-use of this modality that show no statistically significant […]See moreViews95This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Letter to the EditorCabergoline in the Treatment of Peripartum Cardiomyopathy
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
08-01-2016Views95It is premature to make a recommendation for treatment of peripartum cardiomyopathy (PPCM) with prolactin inhibition (bromocriptine or cabergoline) as in the one-case report of Melo et al. There are now multiple reports of trials for PPCM subjects in the use prolactin inhibition treatment compared with non-use of this modality that show no statistically significant […]See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Letter to the Editor Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
08-01-2016
Summary
Letter to the EditorRevista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
08-01-2016Views66This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Letter to the EditorRevista Brasileira de Ginecologia e Obstetrícia. 2016;38(8):423-424
08-01-2016This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
Letter to the Editor
Urine Pregnancy Test before Rubella Vaccination among Reproductive Age Females: An Observation
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(3):160-160
03-01-2016
Summary
Letter to the EditorUrine Pregnancy Test before Rubella Vaccination among Reproductive Age Females: An Observation
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(3):160-160
03-01-2016Views51Dear Editor, Rubella is an important concern in obstetrics. It is a viral illness presenting with fever and skin rash. In a previous report on a seroprevalence study among pregnant women by Ferezin et al, “no patient was positive for IgM, and IgG reactivity was 99.6%.” It should be noted that rubella is an extremely […]See moreViews51This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Letter to the EditorUrine Pregnancy Test before Rubella Vaccination among Reproductive Age Females: An Observation
Revista Brasileira de Ginecologia e Obstetrícia. 2016;38(3):160-160
03-01-2016Views51Dear Editor, Rubella is an important concern in obstetrics. It is a viral illness presenting with fever and skin rash. In a previous report on a seroprevalence study among pregnant women by Ferezin et al, “no patient was positive for IgM, and IgG reactivity was 99.6%.” It should be noted that rubella is an extremely […]See moreThis is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Letter to the Editor Archives - Page 2 of 7 - Revista Brasileira de Ginecologia e Obstetrícia
